Harvard Bioscience Cuts FY26 Adjusted EBITDA Guidance to (1%)-4% From 6%-10%
HBIO has more than doubled off its 52-week low of $4 on elevated volume (2.3× avg).
Summary
Harvard Bioscience furnished its November investor deck alongside 3Q26 results, and it cuts FY26 adjusted EBITDA growth guidance to (1%)-4% from 6%-10% while keeping revenue growth at 3%-5%. The deck also details the $40M debt package, including a $7.5M tranche convertible at $10.00 per share.
Key Events · Earnings and Guidance · HBIO
-
FY26 Adjusted EBITDA Guidance Cut
Full-year adjusted EBITDA growth guidance lowered to (1%)-4% from 6%-10%, while FY26 revenue growth guidance stays at 3%-5%.
-
3Q26 Results Show Margin Squeeze
Revenue of $22.2M (+8% YoY) produced $1.8M of adjusted EBITDA, down from $2.0M a year earlier, with $1.8M of quarterly interest expense.
-
4Q26 Outlook Detailed
Fourth-quarter revenue guided to $23.7M-$25.5M, gross margin 59%-61%, and adjusted EBITDA $3.8M-$4.2M.
-
Debt Terms and Conversion Disclosed
$40M term loan split $10M A / $22.5M B / $7.5M C; Term C converts at $10.00 per share, BroadOak holds warrants for 200K shares at $5.00, rate 12.80% stepping to 12.50%, maturity December 2029.
Analysis · HBIO · Industrial Applications And Services
The 8-K is only a Regulation FD furnishing of the November investor deck, but the deck carries the real news: full-year adjusted EBITDA growth guidance was cut to (1%)-4% from 6%-10%, even as revenue growth guidance holds at 3%-5%. That gap means margin recovery is slipping. In 3Q26, adjusted EBITDA fell to $1.8M from $2.0M a year earlier on $22.2M of revenue, and interest expense of $1.8M in the quarter is eating the improvement. The deck also lays out the $40M debt package in detail: a 12.80% rate stepping to 12.50%, a December 2029 maturity, a $7.5M Term C that converts at $10.00 per share, and BroadOak warrants for 200K shares at $5.00. Against a $9.09 stock near its 52-week high, the $10.00 conversion sits just above the current price, so any further rally pulls that $7.5M toward equity. Project Viking is the offset: $3M of adjusted EBITDA savings in 2027 and $4M a year from 2028 as Holliston production moves to Minneapolis.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HBIO was trading at $9.09 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $41.4M. The 52-week trading range was $4.00 to $9.32. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.